Micell Technologies Receives CE Mark Approval for MiStent SES

07:11 EDT 12 Jun 2013 | PR Newswire
This article has expired, however you can still download the PDF.
Preview:
DURHAM, N.C., June 12, 2013 /PRNewswire/ -- Micell Technologies, Inc. received CE (Conformite Europeenne) Mark approval for its MiStent® Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES®) introducing a thin-strut stent that...

Other Sources for this Article

NEXT ARTICLE

More From BioPortfolio on "Micell Technologies Receives CE Mark Approval for MiStent SES"

Search BioPortfolio:
Advertisement

Relevant Topics

Pharmacy
Latest News Clinical Trials Research Drugs Reports Corporate
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Cardiovascular disease (CVD)
Latest News Clinical Trials Research Drugs Reports Corporate
Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina and heart attack), heart failure, congenital heart disease and stroke. It is also known as heart and circulatory disease. Coron...

Advertisement

Searches Linking to this Story